{"id":7106,"date":"2026-10-22T11:37:54","date_gmt":"2026-10-22T06:07:54","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-22\/"},"modified":"2026-10-22T20:28:30","modified_gmt":"2026-10-22T14:58:30","slug":"sunpharma-share-price-today-2026-10-22","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-22\/","title":{"rendered":"Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.74% | 22 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: SUNPHARMA<\/strong> \u00b7 22 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,758.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+0.74%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,758.00 \/ \u20b91,719.10<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,745.10<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>17.79 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>22 October 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>SUN PHARMACEUTICAL IND L (SUNPHARMA) shares traded higher during the session, gaining 0.74% to settle at \u20b91,758.00 after moving between an intraday low of \u20b91,719.10 and a high of \u20b91,758.00.<\/li>\n<li>Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was supported by pivotal registration study data demonstrating a 55% objective response rate with durable responses and a low incidence of high-grade immune-mediated adverse reactions. This designation follows its prior assignment in metastatic cutaneous squamous cell carcinoma.<\/li>\n<li>Trading volume was 1.18 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Sun Pharmaceutical Ind L share price rising on 22 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">SUN PHARMACEUTICAL IND L (SUNPHARMA) shares traded higher during the session, gaining 0.74% to settle at \u20b91,758.00 after moving between an intraday low of \u20b91,719.10 and a high of \u20b91,758.00.<\/p>\n<p class=\"wt-copy\">The broader market experienced a notable pullback as the Nifty index fell 0.88%, whereas the Nifty Pharma sector benchmark remained relatively resilient, edging down by just 0.07%. Sun Pharma&#x27;s positive session performance helped it outperform both the broader market barometer and its immediate sectoral peer group on the day, building on a modest 0.66% gain over the preceding 5 trading days despite a 4.79% decline over the trailing 20 trading days.<\/p>\n<p class=\"wt-copy\">While the stock demonstrated resilience against broader market weakness, company-specific updates include recent credit rating affirmations from CRISIL and ICRA citing a strong business and financial profile, alongside a recent press release highlighting the elevation of UNLOXCYT to a Category 2A preferred designation in NCCN guidelines for locally advanced cutaneous squamous cell carcinoma. However, these announcements served as background context rather than direct immediate triggers for today&#x27;s price action.<\/p>\n<p class=\"wt-copy\">17.79 lakh shares traded by 22 October 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 15.10 lakh shares (1.18 times). The five-day average daily volume was 15.71 lakh shares. Separately, the NSE report for 22 October 2026 showed 11.72 lakh shares delivered, representing 65.92% of that day\u2019s traded volume. The same report recorded 72,383 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Sector outperformance and steady delivery participation amid broader market weakness<\/strong><\/p>\n<p class=\"wt-copy\">The move appears consistent with stock-specific relative strength and steady institutional delivery participation (65.92% delivery rate) on a day when broader equity benchmarks traded notably lower. No single same-day operational event or announcement was explicitly linked to the session&#x27;s gains.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">UNLOXCYT Receives NCCN Category 2A Preferred Designation<\/div>\n<div class=\"wt-card-date\">20 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was supported by pivotal registration study data demonstrating a 55% objective response rate with durable responses and a low incidence of high-grade immune-mediated adverse reactions. This designation follows its prior assignment in metastatic cutaneous squamous cell carcinoma.<\/p>\n<p class=\"wt-copy\">Enhances the clinical positioning and commercial adoption potential of Sun Pharma&#x27;s innovative oncology portfolio in regulated markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_20102026173321_SE_Intimation_of_Press_Release_on_NCCN_Gudelines_Update.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Credit Rating Affirmations and NCD Programme Assignment<\/div>\n<div class=\"wt-card-date\">13 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">CRISIL Ratings and ICRA Limited assigned &#x27;Crisil AAA\/Stable&#x27; and &#x27;[ICRA]AAA (Stable)&#x27; ratings respectively to the company&#x27;s proposed non-convertible debenture programme of up to INR 10,000 crore while reaffirming existing credit facilities and commercial paper ratings. The rating rationale factors in the company&#x27;s leadership in domestic formulations, robust specialty products portfolio, and financial profile considerations surrounding the proposed acquisition of Organon &amp; Co.<\/p>\n<p class=\"wt-copy\">Reflects high creditworthiness and institutional confidence in the company&#x27;s financial structure and debt-servicing capability.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Resignation of Independent Director Gautam Doshi<\/div>\n<div class=\"wt-card-date\">13 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board of directors took note of the resignation of Mr. Gautam Doshi as a Non-Executive Independent Director effective 12 October 2026, citing personal commitments with no other material reasons stated. Simultaneously, the board approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis up to INR 10,000 crore.<\/p>\n<p class=\"wt-copy\">Represents a board-level governance transition alongside capital-raising authorizations for upcoming strategic initiatives.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">29 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">&#x27;Completion and Result of Postal Ballot dated 25 August 2026&#x27;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_28092026200828_SEIntimationforVR.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">52.68%<\/div>\n<div class=\"wt-note\">54.48% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">14.36%<\/div>\n<div class=\"wt-note\">14.53% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">36.63%<\/div>\n<div class=\"wt-note\">36.71% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1738462_15102026105915_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 13.01% on 30 September 2026. This compares with 12.84% on 30 June 2026, a change of +0.17 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 51 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Value Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">7.70 crore shares \u00b7 3.21%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Nifty 50 Etf<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">6.76 crore shares \u00b7 2.82%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Etf Nifty 50 Bees<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">3.16 crore shares \u00b7 1.32%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1738462_15102026105915_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Upcoming financial results and commentary for the quarter and half year ended 30 September 2026 scheduled for 30 October 2026.<\/li>\n<li>Progress and regulatory approvals regarding the proposed acquisition of Organon &amp; Co.<\/li>\n<li>Commercial uptake and adoption of newly launched specialty products including UNLOXCYT and Leqselvi in regulated markets.<\/li>\n<li>Sustained delivery volume trends and performance relative to the Nifty Pharma sector benchmark.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-21\/\">Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 0.17% | 21 October 2026 \u2014 21 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-15\/\">Sun Pharma in Focus After CRISIL and ICRA Assign NCD Ratings | 15 October 2026 \u2014 15 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-14\/\">Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026 \u2014 14 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/sunpharma\/\">More Sun Pharmaceutical Ind L news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Sun Pharmaceutical Ind L company news?<\/h3>\n<p class=\"wt-copy\">Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was supported by pivotal registration study data demonstrating a 55% objective response rate with durable responses and a low incidence of high-grade immune-mediated adverse reactions. This designation follows its prior assignment in metastatic cutaneous squamous cell carcinoma.<\/p>\n<h3>How strong was Sun Pharmaceutical Ind L\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">17.79 lakh shares traded, 1.18 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-22\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-22\/\"}, \"headline\": \"Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.74% | 22 October 2026\", \"description\": \"Sun Pharmaceutical Ind L share price rose 0.74% to \u20b91,758.00 today. See why SUNPHARMA is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-22T06:07:54Z\", \"dateModified\": \"2026-10-22T20:28:20.982484+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/sunpharma-company-news-2026-10-22.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 20, 2026.\",\"source\":\"NSE\",\"published\":\"20-Oct-2026 17:35:31\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_20102026173321_SE_Intimation_of_Press_Release_on_NCCN_Gudelines_Update.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai \u2013 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA. Reaching People. Touching Lives. 20 October 2026 National Stock Exchange of India Limited Scrip Symbol: SUNPHARMA BSE Limited Scrip Code: 524715 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Press Release Enclosed herewith is a copy of the press release titled \u201cSun Pharma Announces UNLOXCYT \u00ae (cosibelimab- ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not Candidates for Curative Surgery or Curative Radiation\u201d which shall be released after this intimation. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai \u2013 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 FOR IMMEDIATE RELEASE Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not Candidates for Curative Surgery or Curative Radiation MUMBAI, INDIA and PRINCETON, NJ (October 20, 2026 ) \u2013 Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and\/or affiliated companies, \u201cSun Pharma\u201d ) today announced that UNLOXCYT\u00ae (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Category 2A recommended option for patients with locally adv anced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation. This is an addition to the Category 2A designation in metastatic cutaneous squamous cell carcinoma (mCSCC), which was assigned to UNLOXCYT in 2025. UNLOXCYT was approved by the U.S. Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radia tion. The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. UNLOXCYT is the first and only FDA - approved PD-L1-blocking antibody for advanced CSCC (aCSCC). The evidence submitted to NCCN in support of the change was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable: at a median follow -up of 24.1 months; median duration of response had not been reached (range: 8.3 to 31.3+ months). In addition, fewer than 1% of patients experienced a high -grade (Grade 3 -5) immune-mediated adverse reaction (imARs)\u2014an important consideration in this patient population. There were no grade 4 or 5 imARs. \u201cThe NCCN Guidelines play an important role in helping physicians evaluate appropriate treatment options for patients across different disease settings,\u201d said Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma . \u201cThe elevatio n of UNLOXCYT to a Category 2A recommendation for patients with laCSCC marks an important milestone, validating the growing body of clinical evidence supporting UNLOXCYT and reflecting increasing confidence among oncology experts in its role as a treatment option for patients with this challenging disease.\u201d NCCN is an alliance of 34 leading cancer centers in the U.S. Its Clinical Practice Guidelines in Oncology, referred to as the NCCN Guidelines, provide recommendations for the prevention, diagnosis, eval uation, and treatment of different types of cancer. The NCCN Guidelines are among the most influential clinical guidelines in cancer care , offering evidence-based, expert- developed recommendations intended to help clinicians make treatment decisions for pa tients with cancer. One such expert clinician is Dr. Francis Worden, Clinical Professor of Internal Medicine at the University of Michigan Rogel Cancer Center , whose institution is one of the 34 NCCN member cancer centers in the alliance. Dr. Worden said, \u201cThis guideline update reflects the strength of the published evidence supporting the use of UNLOXCYT as first line treatment for laCSCC. In the pivotal study , patients experienced durable and clinically meaningful responses. UNLOXCYT also demonstrated a low incidence of high-grade imARs\u2014an important consideration when selecting immune checkpoint inhibitor therapy for a patient population that is mainly elderly and is often afflicted with other health issues. These clinical outcomes may be explained by the mechanism of action that restores adaptive immunity, engages innate immunity through antibody-dependent cellular cytotoxicity (ADCC), and preserves PD -L2 signaling that may be linked to the presence of some immune tolerance in non-tumor tissues.\u201d NCCN Guidelines also have a meaningful impact on patient access because they inform payer coverage policies, prior-authorization criteria, institutional formularies, and clinical pathways. \u201cFor patients with laCSCC\u2014many of whom are older, medically complex , and vulnerable to treatment-related complications\u2014access to a therapy that offers durable responses together with a low rate of high -grade imARs is especially important. NCCN recognition helps ensure that appropriate patients can receive this treatment up front without unnecessary access barrier s,\u201d said Mark Gimbert, Senior Vice President, Head of Market and Patient Access, North America, Sun Pharma. About Cutaneous Squamous Cell Carcinoma Cutaneous squamous cell carcinoma (CSCC) is among the most common skin cancers worldwide. While early stages are treatable, an estimated 40,000 US patients each year progress to advanced disease, resulting in nearly 15,000 deaths. Important risk factors for CSCC include chronic ultraviole t radiation exposure and immunosuppressive conditions. In addition to being life threatening, CSCC causes significant functional morbidities and cosmetic deformities due to tumors that commonly arise in the head and neck region and that invade blood vessels, nerves, and vital organs such as the eye or ear. About Sun Pharma in Cutaneous Oncology For more than two decades, Sun Pharma has built on its established leadership in dermatology to advance care for people impacted by skin cancer. Working in collaboration with the broader skin cancer community, the company is focused on addressing needs across the disease continuum\u2014from precancerous conditions to advanced skin cancers. With a dedicated cutaneous oncology team and a growing focus in specialty m edicines, Sun Pharma applies scientific rigor, real-world insight, and partnership to support meaningful progress in care and improve continuity for patients, caregivers, and clinicians. Please see the INDICATIONS and IMPORTANT SAFETY INFORMATION below. INDICATIONS AND USAGE UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. IMPORTANT SAFETY INFORMATION WARNING AND PRECAUTIONS Severe and Fatal Immune-mediated Adverse Reactions: Immune-mediated adverse reactions, which can be severe or fatal, can occur in any organ system or tissue, including, but not limited to, immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, and dermatologic adverse reactions. Immune-mediated adverse reactions affecting more than one body system can occur simultaneously. While such adverse reactions usually manifest during treatment, they can also manifest after discontinuation of PD-1\/PD-L1\u2013blocking antibodies. Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue UNLOXCYT based on the severity of reaction. If UNLOXCYT requires interruption or discontinuation, administer systemic corticosteroids (1 to 2 mg\/kg\/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune- mediated adverse reaction is not controlled with corticosteroids. Immune-Mediated Pneumonitis UNLOXCYT can cause immune-mediated pneumonitis. In patients treated with other PD -1\/PD- L1\u2013blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Immune-Mediated Colitis UNLOXCYT can cause immune -mediated colitis, which may present with diarrhea, abdominal pain, and lower gastrointestinal (GI) bleeding. Cytomegalovirus infection\/reactivation has occurred in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1\/PD- L1\u2013blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-Mediated Hepatitis UNLOXCYT can cause immune -mediated hepatitis, defined as requiring the use of systemic corticosteroids and the absence of a clear alternate etiology. Immune-Mediated Endocrinopathies Adrenal Insufficiency UNLOXCYT can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue UNLOXCYT depending on severity Hypophysitis UNLOXCYT can cause immune -mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue UNLOXCYT depending on severity Thyroid Disorders UNLOXCYT can cause immune -mediated thyroid disorders. Thyroiditis c an present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue UNLOXCYT depending on severity Type 1 Diabetes Mellitus, which can present with diabetic ketoacidosis UNLOXCYT can cause type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue UNLOXCYT depending on severity Immune-Mediated Nephritis with Renal Dysfunction UNLOXCYT can cause immune -mediated nephritis, defined as the required use of systemic corticosteroids or other immunosuppressants and the absence of a clear alternate etiology. Immune-Mediated Dermatologic Adverse Reactions UNLOXCYT can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), have occurred with PD-1\/PD-L1\u2013blocking antibodies. Topical emollients and\/or topical corticosteroids may be adequate to treat mild to moderate non-bullous\/exfoliative rashes. Withhold or permanently discontinue UNLOXCYT depending on severity Other Immune-Mediated Adverse Reactions Cardiac\/Vascular: Myocarditis, pericarditis, vasculitis. Nervous System : Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome\/myasthenia gravis (including exacerbation), Guillain -Barre syndrome, nerve paresis, autoimmune neuropathy. Ocular: Uveitis, iritis, ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. Gastrointestinal: Pancreatitis, including increases in serum amylase and lipase levels, gastritis, duodenitis. Musculoskeletal and Connective Tissue : Myositis\/polymyositis, rhabdomyolysis and associate d sequelae including renal failure, arthritis, polymyalgia rheumatica. Endocrine: Hypoparathyroidism. Hematologic\/Immune: Autoimmune hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection. Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-like) Overlap Syndrome, reporting as the co-occurrence of either two or all three adverse reactions. Infusion-Related Reactions: UNLOXCYT can cause severe or life-threatening infusion-related reactions. Monitor patients for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion or permanently discontinue UNLOXCYT based on severity of reaction. Consider premedication with an antipyretic and\/or an antihistamine for patients who have had previous system reactions to infusions of therapeutic proteins. Complications of Allogeneic HSCT: Fatal and other serious complications can occur in patients who receive allogeneic Hematopoietic Stem Cell Transplantation (HSCT) before or after being treated with a PD-1\/PDL1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). Embryo-Fetal Toxicity\/Females and Males of Reproductive Potential: UNLOXCYT can cause fetal harm when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential prior to initiating UNLOXCYT. Females should use effective contraception during treatment with UNLOXCYT and for 4 months after the last dose. Advise female patients not to breastfeed during treatment with UNLOXCYT and for 4 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (\u226510%) were fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, localized infection, and urinary tract infection. USE IN SPECIFIC POPULATIONS Lactation: Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 4 months after the last dose of UNLOXCYT. To report side effects of UNLOXCYT to FDA: visit www.fda.gov\/medwatch or call 1 - 800FDA-1088. Report SUSPECTED ADVERSE REACTIONS or any side effects or ADEs (adverse drug events) to our Drug Safety Department at 1 -800-406-7984 or DrugSafety.USoperations@sunpharma.com (preferred) with as much information as available. Please see Full Prescribing Information for additional Important Safety Information. About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050) Sun Pharma is the world\u2019s leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthca re products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as Global Emerging Markets. Sun\u2019s high growth Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and on co-dermatology and accounts for about 20% of company sales. The company\u2019s vertically integrated operations deliver high -quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi -cultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (formerly Twitter). Disclaimer Statements in this \\\"Document\\\" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be \\\"forward looking statements\\\" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments\/circumstances after the date hereof. Contacts: Sun Pharma Investors: Dr. Abhishek Sharma Tel + 91 22 4324 4324, Ext 2929 Tel Direct + 91 22 43242929 Mobile + 91 98196 86016 E-mail abhi.sharma@sunpharma.com U.S. Media: Robert Perry Mobile +1 609 921 4267 E-mail robert.perry@sunpharma.com \u00a9 2026 Sun Pharmaceutical Industries, Inc. All rights reserved. PM-US-ULX-0344 10\/26 ###\"},{\"summary\":\"'Completion and Result of Postal Ballot dated 25 August 2026'.\",\"category\":\"Updates\",\"date\":\"28-Sep-2026 20:09:05\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_28092026200828_SEIntimationforVR.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Resignation of Director of the Company.\",\"category\":\"Resignation\",\"date\":\"12-Oct-2026 20:05:00\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026200413_BMOutcome12October2026.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"'Completion and Result of Postal Ballot dated 25 August 2026'.\",\"category\":\"Updates\",\"date\":\"28-Sep-2026 20:09:05\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_28092026200828_SEIntimationforVR.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Resignation of Director of the Company.\",\"category\":\"Resignation\",\"date\":\"12-Oct-2026 20:05:00\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026200413_BMOutcome12October2026.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":52.68,\"public_pct\":47.32,\"fii_pct\":14.36,\"dii_pct\":22.27,\"mf_pct\":13.01,\"institutional_pct\":36.63,\"noninst_pct\":10.7,\"mf_scheme_count\":51,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Icici Prudential Value Fund\",\"shares\":76999673,\"pct\":3.21},{\"name\":\"Sbi Nifty 50 Etf\",\"shares\":67635113,\"pct\":2.82},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Etf Nifty 50 Bees\",\"shares\":31568415,\"pct\":1.32},{\"name\":\"Hdfc Trustee Company Ltd. A\/C Hdfc Balanced Advantage Fund\",\"shares\":27282287,\"pct\":1.14}],\"period\":\"30-SEP-2026\",\"submission_date\":\"15-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1738462_15102026105915_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":54.48,\"previous_fii_pct\":14.53,\"previous_dii_pct\":22.18,\"previous_mf_pct\":12.84,\"previous_institutional_pct\":36.71,\"previous_mf_scheme_count\":49,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794\",\"side\":\"Buy\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"},{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828\",\"side\":\"Sell\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Ind L share price rose 0.74% to \u20b91,758.00 today. See why SUNPHARMA is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":7105,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.74% | 22 October 2026","_witty_meta_description":"Sun Pharmaceutical Ind L share price rose 0.74% to \u20b91,758.00 today. See why SUNPHARMA is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Sun Pharmaceutical Ind L share price today","_witty_reason_label":"Sector outperformance and steady delivery participation amid broader market weakness","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[199],"class_list":["post-7106","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-sunpharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=7106"}],"version-history":[{"count":4,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7106\/revisions"}],"predecessor-version":[{"id":7463,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7106\/revisions\/7463"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/7105"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=7106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=7106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=7106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}